Changchun Zhou

Changchun Zhou


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2023 in Cancer Medicine
Verified
Journal Article
Open access
CZChangchun Zhou
Changchun Zhou
YWYuanbo Wu
Yuanbo Wu
ZWZeyu Wang
Zeyu Wang
YLYanli Liu
Yanli Liu
JYJiaqi Yu
Jiaqi Yu
AHAina He
Aina He
Establishing a valid in vitro model to represent tumor heterogeneity and biology is critical but challenging. Tumor organoids are self‐assembled three‐dimensional cell clusters which are of great significance for recapitulating the histopathological, genetic, and phenotypic characteristics of primary tissues. The organoid has emerged as an attractive in vitro platform for tumor biology research and high‐throughput drug screening in cancer medicine. Organoids offer unique advantages over cell lines and patient‐derived xenograft models, but there are no standardized methods to guide the culture of organoids, leading to confusion in organoid studies that may affect accurate judgments of tumor biology. This review summarizes the shortcomings of current organoid culture methods, presents the latest research findings on organoid standardization, and proposes an outlook for organoid modeling.

9 September 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CFChuanbo Fan
Chuanbo Fan
JWJinyu Wei
Jinyu Wei
CYChenglu Yuan
Chenglu Yuan
XWXin Wang
Xin Wang
CJChuanwu Jiang
Chuanwu Jiang
MYMing Yang
Ming Yang
As a heterogeneous kind of malignances, Non-Hodgkin lymphoma (NHL) is the most common hematologic cancer worldwide with the significantly increased morbidity in China. Accumulated evidences demonstrated that oncoprotein MDM4 plays a crucial role in the TP53 tumor suppressor signaling pathway. An rs4245739 A>C polymorphism locating in the MDM4 3′-untranslated region creates a miR-191 target site and results in allele-specific MDM4 expression. In this study, we examined the association between this polymorphism as well as the TP53 Arg72Pro (rs1042522 G>C) genetic variant and Non-Hodgkin Lymphoma (NHL) risk in a Chinese Han population. Genotypes were determined in 200 NHL cases and 400 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by logistic regression. We found significantly increased NHL risk among carriers of the TP53 72Pro allele compared with those with the 72Arg allele (P = 0.002 for the Pro/Pro genotype). We also observed a significantly decreased NHL risks among carriers of the MDM4 rs4245739 C allele compared with those with the A allele in Chinese (P = 0.014 for the AC genotype). Stratified analyses revealed the associations between these SNPs and NHL risk are especially noteworthy in young or male individuals. Additionally, the associations are much pronounced in NHL patients with B-cell lymphomas or grade 3 or 4 disease. Our results indicate that the TP53 Arg72Pro and the MDM4 rs4245739 polymorphisms contribute to NHL susceptibility and support the hypothesis that genetic variants in the TP53 pathway genes can act as important modifiers of NHL risk.

25 July 2013 in Gene
Verified
Journal Article
Closed access
JWJiwen Wang
Jiwen Wang
JGJia Gao
Jia Gao
YLYingjie Li
Yingjie Li
XZXiaoxia Zhao
Xiaoxia Zhao
WGWei Gao
Wei Gao
CZChangchun Zhou
Changchun Zhou

12 September 2014 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
HWHaiyong Wang
Haiyong Wang
LTLei Tong
Lei Tong
JWJinyu Wei
Jinyu Wei
WPWenting Pan
Wenting Pan
LLLichao Li
Lichao Li
MYMing Yang
Ming Yang

27 May 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
XLXinyu Li
Xinyu Li
TLTao Li
Tao Li
YZYan Zhao
Yan Zhao
JSJunqi Shan
Junqi Shan
YGYang Gao
Yang Gao
YSYanlai Sun
Yanlai Sun
Background: Colorectal cancer (CRC) is the third most common malignant tumor type all over the world with high mortality. Chemoresistance of CRC leads to treatment failure and disease aggravation. We previously identified Hsa_circ_0020095 as a novel oncogene to promote progression and cisplatin-resistance in colon cancers by modulating the miR-487a-3p/SOX9 axis.Methods: Patient-derived organoids (PDOs) were generated from CRC patients and validated by H&E staining, immunohistochemistry (IHC), and whole exome sequencing (WES). Hsa_circ_0020095 was knocked down in PDOs by shRNA and the inhibition of hsa_circ_0020095 was determined using RT-qPCR. The RNA samples analyzed separately, and then pooled together for KEGG and GO analyses. The effects of knocking down hsa_circ_0020095 on drug-resistance of PDOs were examined using CellTiter-Glo®3D Cell viability assay. Finally, the underlying mechanism was explored by transcriptomic sequencing and subsequent bioinformatics analyses.Results: Five organoid lines were successfully established from CRC patients using surgically resected tumor samples. PDOs resembled their parental tumor tissues in morphology, histopathology, and genetic alterations. Silencing of circ_0020095 resulted in remarkable inhibition of hsa_circ_0020095 in PDOs and reversed the resistance of PDOs to 5-FU and oxaliplatin. Mechanistically, hsa_circ_0020095 may function by modulating key pathways and biological functions involved in pathophysiological processes in CRC.Conclusion: Hsa_circ_0020095 modulates chemoresistance of CRC, which could potentially be explored as a therapeutic target for CRC treatment.